linjc16/ctgov huggingface dataset:
Effect of Nasal Highflow on Right Heart Function

Study Overview
=================
Brief Summary
-----------------
In this study effect of NHF on pulmonary thermodynamic parameters will studied.

Official Title
-----------------
Hemodynamic Effects of Nasal Highflow on Patients With Chronic Respiratory Insufficiency and Pulmonary Hypertension

Conditions
-----------------
Pulmonary Hypertension

Intervention / Treatment
-----------------
* Device: Nasal high flow (NHF) supplementation
* Device: oxygen supplementation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: stable disease hypoxemic respiratory disorder Exclusion Criteria: decompensation acute illness
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: oxygen supplementation<br>right heart catheterization will be done in hypoxemic patients with supplemental oxygen | Device: oxygen supplementation<br>* hypoxemic patients will use their normal oxygen supplementation durch right heart catheterization<br>|
| Active Comparator: Nasal high flow (NHF) supplementation<br>right heart catheterization after during NHF (20 min) use with 35 l/min | Device: Nasal high flow (NHF) supplementation<br>* use of NHF for 20 min/ 35 l/min, at the end of this period right heart catheterization<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| changes in mean pulmonary pressure (PAPm) | measured in mmHg | 20 min | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| changes in wedge pressure (PC) | mmHg | 20 min | 
| changes in cardiac index (CI) | l/min/qm | 20 min | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
NHF, pulmonary hypertension
Prevelance of Dental Caries in Agroup of Egyption Children Using Caries Assessment Spectrum and Treatment

Study Overview
=================
Brief Summary
-----------------
To explore the prevalence of dental caries in Egyptian children aged from 6 to 9 years oldusing CAST index and DMFT index

Detailed Description
-----------------
To explore the prevalence of dental caries in Egyptian children aged from 6 to 9 years oldusing CAST index and DMFT index. from MUST university outpatient clinic

Official Title
-----------------
Prevelance of Dental Caries in Agroup of Egyption Children Using Caries Assessment Spectrum and Treatment

Conditions
-----------------
Dental Caries

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Parental or guardian acceptance for participation in the study. Children who are medically free from any systemic diseases. Children with mixed dentition aging from 6-9 years old. Both genders. Exclusion Criteria: uncooperative patient

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 9 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevelance of caries using dmft index | MDFT index | 3month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevelance of caries index using cast index | CAST index | 3 month |
Vitamin D as a Key Player in Rheumatoid Arthritis

Study Overview
=================
Brief Summary
-----------------
Rheumatoid arthritis (RA) is a systemic, chronic and inflammatory disease of joints linked to autoimmunity. Vitamin D was found to modulate cell growth, function of immune cells and anti-inflammatory action. The aim of this study was to investigate serum vitamin D level and some cytokines and to identify the correlation between vitamin D and these cytokines in RA. Methods: Totally 60 RA patients without vitamin D supplement were involved in this study. The serum level of vitamin D, interleukin-6 (IL-6), IL-10, IL-35, tumor necrosis factor α (TNF-α) and C-reactive protein (CRP) were measure in all patients by enzyme-linked immunosorbent assay (ELISA) then they will divided into 2 groups, group I receive vit. D supplementation and group II will receive placebo and follow up for 3 months.

Detailed Description
-----------------
Rheumatoid arthritis (RA) is a systemic, chronic and inflammatory disease of joints linked to autoimmunity. Vitamin D was found to modulate cell growth, function of immune cells and anti-inflammatory action. The aim of this study was to investigate serum vitamin D level and some cytokines and to identify the correlation between vitamin D and these cytokines in RA. Methods: Totally 60 RA patients without vitamin D supplement were involved in this study. The serum level of vitamin D, interleukin-6 (IL-6), IL-10, IL-35, tumor necrosis factor α (TNF-α) and C-reactive protein (CRP) were measure in all patients by enzyme-linked immunosorbent assay (ELISA) then they will divided into 2 groups, group I receive vit. D supplementation and group II will receive placebo and follow up for 3 months.

Official Title
-----------------
Vitamin D as a Key Player in Rheumatoid Arthritis Immune Response

Conditions
-----------------
the Immunomodulatory Effect

Intervention / Treatment
-----------------
* Drug: Vitamin D
* Drug: Steroid Drug


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: RA patients Exclusion Criteria: Patients with inflammatory bowel disease patients with any other autoimmune diseases

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Vit D<br> | Drug: Vitamin D<br>* vitamin D supplementation<br>|
| Active Comparator: control<br> | Drug: Steroid Drug<br>* control<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| disease activity score 28 | disease activity score | 3 months |
AGN 201904 Versus Esomeprazole in the Prevention of Aspirin-induced Stomach or Upper Intestinal Damage in Healthy Volunteers

Study Overview
=================
Brief Summary
-----------------
AGN 201904, a proton pump inhibitor, versus esomeprazole in the prevention of stomach or upper intestinal damage following administration of high-dose aspirin in healthy volunteers

Conditions
-----------------
Peptic Ulcer

Intervention / Treatment
-----------------
* Drug: AGN 201904
* Drug: esomeprazole


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy Adult Volunteers who have provided written informed consent Exclusion Criteria: Volunteers with a history of upper gastrointestinal disease or who have a current diagnosis of upper gastrointestinal disease. Female volunteers who pregnant, nursing, or planning a pregnancy Volunteers with a history of drug or alcohol abuse

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Drug: AGN 201904<br> <br> |
| Active Comparator: 2<br> | Drug: esomeprazole<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Stomach or upper intestinal erosions |  |  |
Helicobacter Pylori and Proton Pump Inhibitor

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to know the distribution of HP in stomach before use of PPI, during use of PPI, and after stop of PPI.

Detailed Description
-----------------
Endoscopy and biopsy will be performed to investigate the distrubition of HP before, during, and after using PPI.

Official Title
-----------------
Distribution of Helicobacter Pylori According to the Use of Proton Pump Inhibitor

Conditions
-----------------
Helicobacter Infections

Intervention / Treatment
-----------------
* Drug: PPI (proton pump inhibitor)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who are indicated to endoscopic resection due to gastric neoplasm Aged between 19 to 65 years Informed consent Exclusion Criteria: Previous history of HP eradication Previous history of PPI use within 6 months No HP infection

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Helicobacter pylori(HP) positive<br>Participants who are diagnosed with Helicobacter Pylori infection through ESD(endoscopic submucosal dissection) will be treated with PPI (proton pump inhibitor). | Drug: PPI (proton pump inhibitor)<br>* Pre ESD (endoscopic submucosal dissection) Assessment atrophy and metaplasia in stomach, Check Helicobacter pylori Use of PPI for 2 months Post ESD 1 (After 2 months) Assess the distribution of helicobacter pylori after using PPI. Stop of PPI Post ESD 2 (After 4 months) Assess the distribution of helicobacter pylori after stop of PPI.<br>* Other names: pantoprazole, lansoprazole, dexlansoprazole, rabeprazole;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Analysis the change of Helicobacter pylori distribution according to the use of proton pump inhibitor |  | Change in the distribution of Helicobacter Pylori(HP) at 4 months. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Analysis the change of HP distribution according to the use of PPI in atrophic change of stomach |  | Change in the distribution of Helicobacter Pylori(HP) at 4 months. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Stomach Neoplasms, proton pump inhibitor, endoscopic submucosal dissection, Helicobacter pylori, Gastritis, Atrophic
Dose Reduction in Thoracic CT

Study Overview
=================
Brief Summary
-----------------
Hypothesis: Does a 50% reduction in radiation in dose significantly affect the diagnostic quality of chest CT

Detailed Description
-----------------
Patients with Lymphoma are recruited and have a follow up CT performed at 50% of the standard exposure parameters. The studies are compared for image quality with a recent (<3 months) thoracic CT performed at standard exposure parameters.

Official Title
-----------------
Dose Reduction in Thoracic CT: A Comparison of on Line Automatic Dose Reduction and a 50% Reduction in Dose

Conditions
-----------------
Lymphoma

Intervention / Treatment
-----------------
* Device: CT Thorax


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with Lymphoma Exclusion Criteria: No recent (<3 months) thoracic CT

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: CT Thorax|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluating the diagnostic quality of thoracic CT exams performed at 50% of standard dose parameters |  |  |
Phase II Randomized Study of Muromonab-CD3, Cyclosporine, Methylprednisolone, and Prednisone in Patients With Giant Cell Myocarditis

Study Overview
=================
Brief Summary
-----------------
OBJECTIVES: I. Assess the effect of immunosuppression with muromonab-CD3, cyclosporine, methylprednisolone, and prednisone versus standard care in terms of death, heart transplantation, or left ventricular assistive device placement in patients with giant cell myocarditis. II. Compare left ventricular ejection fraction prior to and after 4 weeks of treatment in these arms. III. Compare the degree of myocardial inflammatory infiltrate prior to and after 4 weeks of treatment in these arms.

Detailed Description
-----------------
PROTOCOL OUTLINE: This is a randomized, open label, multicenter study. Patients are randomized to receive standard care with immunosuppression (arm I) or standard care with or without immunosuppression (no muromonab-CD3 or cyclosporine)(arm II). Arm I: Patients receive methylprednisolone IV once daily for 3 days and muromonab-CD3 IV once daily for 10 days. Oral cyclosporine is administered twice daily and oral prednisone is administered once daily for 1 year. Arm II: Patients receive standard care with or without immunosuppression (no muromonab-CD3 or cyclosporine). Patients are followed for one year.

Conditions
-----------------
Myocarditis, Giant Cell Myocarditis

Intervention / Treatment
-----------------
* Drug: Cyclosporine
* Drug: methylprednisolone
* Drug: Muromonab-CD3
* Drug: prednisone


Participation Criteria
=================
Eligibility Criteria
-----------------
PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Idiopathic giant cell myocarditis confirmed by endomyocardial biopsy Heart failure and/or arrhythmia of less than 3 months duration --Patient Characteristics-- Hepatic: AST/ALT no greater than 3 times upper limit of normal Renal: Creatinine no greater than 2.5 mg/dL Other: Not pregnant or nursing; Negative pregnancy test; Fertile patients must use effective contraception; No clinical evidence of sepsis or active infection (e.g. meningitis, osteomyelitis, etc.); No contraindication to immunosuppression; No allergy to cyclosporine or muromonab-CD3; No other severe concurrent diseases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Cyclosporine|nan|
|Drug: methylprednisolone|nan|
|Drug: Muromonab-CD3|nan|
|Drug: prednisone|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cardiovascular and respiratory diseases, giant cell myocarditis, rare disease
The Correlation of Myodural Bridges to Biomechanical Parameters in Patients Suffering From Primary Chronic Neck Pain

Study Overview
=================
Brief Summary
-----------------
In recent years, an anatomical connection of suboccipital muscle fibers to the dura has been found in pathological studies. The physiologic function of these fibers is still unknown. Using Magnetic Resonance Tomography (MRI), this study will investigate whether these fibers undergo changes in patients suffering from primary chronic neck pain. In addition, the biomechanical parameters of neck movements in these patients will be correlated with the imaging findings.

Conditions
-----------------
Neck Pain

Intervention / Treatment
-----------------
* Other: Biomechanical parameters
* Other: MRI


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Chronic Neck Pain Exclusion Criteria: Have undergone cervical spine surgery Known cerebral vascular disease of the carotid or vertebral arteries Malignant disease of the cervical spine

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Primary Chronic Neck Pain<br>Patients suffering for at least 3 years from neck pain without any underlying pathology who have undergone MRI. Biomechanical parameters of neck movements will be investigated. | Other: Biomechanical parameters<br> <br> Other: MRI<br>* MRI of cervical spine<br>|
| Control<br>Patients without neck pain who have undergone MRI for any reason. Biomechanical parameters of neck movements will be investigated. | Other: Biomechanical parameters<br> <br> Other: MRI<br>* MRI of cervical spine<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Volume and Number of Muscle Fibers in Myodural Bridges | A composite outcome including the interpretation, counting and measurement of muscle fibers as found on MRI | One hour | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measurement of cervical range of motion | Measurements will be made using a cervical range of motion device (CROM Device) | Two hours |
Using Continuous Glucose Monitoring to Understand the Glycemic Impact of Food

Study Overview
=================
Brief Summary
-----------------
This study will look at the impact that meals have on blood glucose (sugar) levels. Subjects will be asked to use a Continuous Glucose Monitoring System (CGM), which monitors glucose levels continuously. Breakfast and lunch meals will be provided and must be consumed at the International Diabetes Center.

Official Title
-----------------
Using Continuous Glucose Monitoring to Understand the Glycemic Impact of Food

Conditions
-----------------
Type 2 Diabetes, Currently Taking Metformin

Intervention / Treatment
-----------------
* Other: Continuous Glucose Monitoring of Carbohydrate Intake


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female or male Age 18 and older Diagnosed with type 2 diabetes for a minimum of 6 months Is taking metformin for diabetes management; no other diabetes medications Has been on a stable dose of metformin for at least 3 months HbA1c is 7% or greater and less than 9%; >7% or <9% BMI <30kg/m2 Willing to give informed consent No evidence of acute illness, fever, undue stress Motivated and capable of following the protocol and instructions provided by the healthcare professional Available for the study on the scheduled visit days Access to telephone communications Exclusion Criteria: Under 18 years of age Has not been diagnosed with type 2 diabetes for a minimum of 6 months Is currently taking other diabetes medications in addition to metformin Has taken other diabetes medications within the past 3 months HbA1c <7% or >9% BMI > 30kg/m2 Unable to follow the study protocol No access to telephone communications Unable to read and write in English Unable to maintain their health, or have undue stress Skin abnormalities at the insertion sites that would confound assessment of the effect of the device on the skin Allergy to adhesives Any concomitant medical condition that would likely affect the evaluation of device performance Taken oral or inhaled prednisone or cortisone medications in the previous 30 days

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Metformin, Type 2 Diabetes<br> | Other: Continuous Glucose Monitoring of Carbohydrate Intake<br>* Subjects eat standard breakfast and lunch and keep food records.<br>* Other names: Navigator CGM System;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Glycemic Response to the Fixed Meal |  | 4 hour meal test |